Danske Bank A S Invests $279.61 Million in AbbVie Inc. $ABBV

Key Points

• Danske Bank A/S bought 1,207,605 shares of AbbVie in Q3, an investment valued at about $279.61 million that makes AbbVie roughly 0.7% of Danske’s portfolio and its 19th largest holding; Danske owned about 0.07% of AbbVie at quarter-end.
• AbbVie delivered a quarter beat and set FY‑2026 guidance, reporting $2.71 EPS (vs. $2.65 expected) and $16.62 billion revenue, with FY‑2026 EPS guidance of $14.370–$14.570, and announced a $1.73 quarterly dividend (annualized $6.92, ~3.1% yield).
• Notable ownership and activity: institutional investors own about 70% of the stock, analysts rate AbbVie as a "Moderate Buy" with an average target near $253.15, and insiders recently sold shares (EVP Perry Siatis sold ~22,381 shares and SVP David Purdue sold ~5,230 shares).

Danske Bank A S purchased a new stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,207,605 shares of the company's stock, valued at approximately $279,609,000. AbbVie comprises about 0.7% of Danske Bank A S's investment portfolio, making the stock its 19th largest position. Danske Bank A S owned about 0.07% of AbbVie at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ABBV. Provident Investment Management Inc. grew its stake in AbbVie by 1.2% during the third quarter. Provident Investment Management Inc. now owns 6,007 shares of the company's stock worth $1,391,000 after buying an additional 70 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt raised its stake in shares of AbbVie by 6.3% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 137,770 shares of the company's stock valued at $31,891,000 after acquiring an additional 8,200 shares during the last quarter. Garrett Wealth Advisory Group LLC raised its stake in shares of AbbVie by 5.6% in the third quarter. Garrett Wealth Advisory Group LLC now owns 4,011 shares of the company's stock valued at $929,000 after acquiring an additional 213 shares during the last quarter. Apexium Financial LP boosted its holdings in shares of AbbVie by 2.5% in the 3rd quarter. Apexium Financial LP now owns 5,739 shares of the company's stock worth $1,329,000 after acquiring an additional 141 shares in the last quarter. Finally, Greenline Partners LLC bought a new stake in AbbVie during the 3rd quarter worth approximately $453,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Alloy Therapeutics signed a multi‑year agreement with AbbVie to develop a next‑generation antibody discovery platform; Alloy will receive an upfront payment plus milestones, which can accelerate discovery of hard‑to‑drug targets and provide non‑dilutive near‑term cash. Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform
• Positive Sentiment: William Blair reiterated confidence in AbbVie’s growth prospects tied to obesity treatment progress after positive Phase 1 results — this underscores potential upside from a new high‑growth therapeutic area beyond core franchises. William Blair Asserts AbbVie Inc. (ABBV) Growth Prospects on Obesity Treatment Opportunities
• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) launched a Skin Quality Index to standardize patient/provider conversations in aesthetics — a marketing and product‑positioning move that can support elective‑procedure demand and cross‑sell across Allergan’s portfolio. AbbVie’s Skin Quality Index Aims To Shape Aesthetics Growth Narrative
• Positive Sentiment: Notable institutional interest: Billionaire Ken Fisher’s fund has included AbbVie among its notable 2026 moves, signaling confidence from an established investor and potential buying support. AbbVie Inc. (ABBV): Billionaire Ken Fisher Admires This Pharma Stock
• Neutral Sentiment: Zacks and other analysts highlight AbbVie as a strong value stock based on valuation metrics and steady cash flows — useful context for longer‑term investors but not an immediate price catalyst. Here's Why AbbVie (ABBV) is a Strong Value Stock
• Neutral Sentiment: A U.S. appeals court revived a whistleblower lawsuit alleging overcharging on drugs for low‑income patients against several large drugmakers, creating a sector‑level legal overhang; it’s unclear from published reports whether AbbVie is a named defendant, but the ruling increases regulatory/legal risk for big pharma generally. Big drugmakers must face US overcharge claims on medications for low-income patients
• Negative Sentiment: Technical pressure — several market writeups note ABBV has slipped below its 50‑day simple moving average, signaling short‑term momentum weakness and prompting traders to take profits or wait for a dip to re‑enter. AbbVie Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?

Insider Transactions at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the business's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares of the company's stock, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.08% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on ABBV. Evercore dropped their price target on AbbVie from $232.00 to $228.00 and set an "outperform" rating for the company in a report on Wednesday, February 4th. Weiss Ratings reissued a "hold (c)" rating on shares of AbbVie in a research note on Wednesday, January 21st. UBS Group decreased their target price on AbbVie from $240.00 to $230.00 and set a "neutral" rating on the stock in a report on Thursday, February 5th. Royal Bank Of Canada assumed coverage on AbbVie in a research note on Tuesday, February 24th. They issued an "outperform" rating and a $260.00 target price for the company. Finally, Sanford C. Bernstein reaffirmed a "market perform" rating on shares of AbbVie in a report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $253.15.

AbbVie Price Performance

ABBV stock opened at $219.96 on Wednesday. The company has a 50 day moving average price of $224.27 and a 200 day moving average price of $224.95. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The stock has a market capitalization of $388.92 billion, a PE ratio of 93.20, a price-to-earnings-growth ratio of 0.77 and a beta of 0.34.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts' consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business's quarterly revenue was up 10.0% compared to the same quarter last year. During the same period last year, the company earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.1%. AbbVie's dividend payout ratio (DPR) is currently 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.